The House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug costs and strengthen the Affordable Care Act’s health insurance marketplaces. The legislation’s drug-related provisions would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief, and help decrease the time it takes for generic competitors to get to market. The ACA marketplace provisions would provide funding to expand navigator support and outreach to help consumers enroll in individual market coverage, and void a final rule that expanded short-term limited duration health plans. 
 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The Department of Health and Human Services June 26 announced beneficiary coinsurance reductions for 64 prescription drugs available through Medicare Part B.…
Headline
The U.S. Court of Appeals for the 5th Circuit June 21 partially affirmed the district court judgment that the Preventative Services Task Force charged with…
Headline
The AHA May 22 released a new infographic and blog highlighting how increasing drug prices and shortages are jeopardizing patient access to hospital care and…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…